Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Fineline Cube Jan 15, 2026
Company Deals

Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy

Fineline Cube Jan 15, 2026
Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Fineline Cube Jan 15, 2026
Company Deals

WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Fineline Cube Jan 15, 2026
Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Fineline Cube Jan 15, 2026
Company Deals

CN Bio and Pharmaron Partner to Validate and Expand OOC Technology Applications

Fineline Cube Apr 25, 2025

CN Bio, a UK-based provider of Organ-on-a-chip (OOC) systems and solutions, has entered into a...

Company

Gan & Lee Pharmaceuticals Reports 417 Million USD Revenue and 80.75% Profit Surge in 2024

Fineline Cube Apr 25, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) reported revenues of RMB 3.045 billion (USD 417 million)...

Company Drug

Hepalink Secures SAHPRA Approval for Ivenoxin in South Africa

Fineline Cube Apr 25, 2025

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE: 002399, HKG: 9989) has announced that it has...

Company Drug

Akeso’s Penpulimab Gains FDA Approval for Nasopharyngeal Carcinoma Treatment

Fineline Cube Apr 25, 2025

China-based Akeso, Inc. (HKG: 9926) announced that it has received marketing approval from the US...

Company

Sanofi Reports Q1 Sales Growth Driven by Dupixent and New Product Launches

Fineline Cube Apr 25, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) released its Q1 2025 financial results, reporting global net...

Company Deals

Shineco Inc. Announces Acquisition of InfiniClone for Regenerative Medicine Expansion

Fineline Cube Apr 24, 2025

US-based Shineco Inc. (NASDAQ: SISI) announced that its subsidiary Shineco Life Sciences Group Hong Kong...

Company Deals

Shenzhen Core Medical Closes Series D Round to Advance Miniaturized Artificial Hearts

Fineline Cube Apr 24, 2025

Shenzhen Core Medical Technology Co., Ltd, a developer of mechanical circulation assist systems, has reportedly...

Company Drug

Doer Biologics Begins Phase II Study of DR10624 for Steatotic Liver Disease

Fineline Cube Apr 24, 2025

China-based Zhejiang Doer Biologics Co., Ltd has announced the first patient dosing in a Phase...

Company Deals Drug

Boehringer Ingelheim Partners with Tessellate Bio on ALT Cancer Therapies

Fineline Cube Apr 24, 2025

Boehringer Ingelheim (BI), a German pharmaceutical leader, has entered into a strategic collaboration and global...

Company Deals

Genentech Collaborates with Repertoire Immune Medicines on Autoimmune Disease Therapies

Fineline Cube Apr 24, 2025

Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY) , announced a collaboration...

Company Deals

AstraZeneca Expands AI Partnership with Tempus AI and Pathos AI for Oncology Research

Fineline Cube Apr 24, 2025

UK pharmaceutical leader AstraZeneca (AZ, NASDAQ: AZN) has expanded its collaboration with US-based Tempus AI,...

Company

Boston Scientific Reports 20.9% Revenue Growth in Q1 2025 Financial Results

Fineline Cube Apr 24, 2025

US medical technology giant Boston Scientific Corporation (NYSE: BSX) released its Q1 2025 financial report,...

Company Medical Device

Roche Launches Navify Chest Pain Triage Algorithm With CE Mark

Fineline Cube Apr 24, 2025

Swiss healthcare giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that it has received CE...

Policy / Regulatory

Trump Administration Considers Tying US Drug Prices to International Benchmarks

Fineline Cube Apr 24, 2025

Reuters reported that the Trump administration is exploring a policy to tie domestic drug prices...

Company Deals Drug

Baheal Partners with Jiluntai for Commercialization of Technetium-99m-labeled Imaging Agent

Fineline Cube Apr 24, 2025

China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) has entered into a...

Company

PingAn Good Doctor Reports Q1 2025 Revenue Growth and Net Profit Turnaround

Fineline Cube Apr 24, 2025

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...

Company Medical Device

MicroPort MedBot Gains NMPA Clearance for Toumai’s Remote Surgery Across Departments

Fineline Cube Apr 24, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced receiving clearance from China’s National...

Company Deals

QYuns Therapeutics Signs Global Licensing Deal with Caldera for Autoimmune BsAb

Fineline Cube Apr 24, 2025

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has entered into a licensing agreement with...

Company

Roche Unveils $50 Billion Five-Year US Investment Plan to Expand Manufacturing and R&D

Fineline Cube Apr 23, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced a five-year investment plan totaling...

Company Deals

China Medical System Announces Spin-off of Dermavon for HKEX IPO

Fineline Cube Apr 23, 2025

China Medical System Holdings Limited (CMS; HKG: 0867) has announced the spin-off of its dermatology-focused...

Posts pagination

1 … 116 117 118 … 610

Recent updates

  • Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
  • Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%
  • Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic
  • Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination
  • Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.